{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:32:07Z","timestamp":1789500727301,"version":"build-2803163510"},"reference-count":96,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["R01CA237027"],"award-info":[{"award-number":["R01CA237027"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["R01CA240290"],"award-info":[{"award-number":["R01CA240290"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["R21CA237939"],"award-info":[{"award-number":["R21CA237939"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["R21CA218635"],"award-info":[{"award-number":["R21CA218635"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"RPCCC and NCI center","doi-asserted-by":"publisher","award":["R01CA237027"],"award-info":[{"award-number":["R01CA237027"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"RPCCC and NCI center","doi-asserted-by":"publisher","award":["R01CA240290"],"award-info":[{"award-number":["R01CA240290"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"RPCCC and NCI center","doi-asserted-by":"publisher","award":["R21CA237939"],"award-info":[{"award-number":["R21CA237939"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"RPCCC and NCI center","doi-asserted-by":"publisher","award":["R21CA218635"],"award-info":[{"award-number":["R21CA218635"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"RPCCC and NCI center","doi-asserted-by":"publisher","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Prostate cancer (PCa) is a highly heterogeneous disease and typically presents with multiple distinct cancer foci. Heterogeneity in androgen receptor (AR) expression levels in PCa has been observed for decades, from untreated tumors to castration-resistant prostate cancer (CRPC) to disseminated metastases. Current standard-of-care therapies for metastatic CRPC can only extend life by a few months. Cancer stem cells (CSCs) are defined as a subpopulation of cancer cells that exists in almost all treatment-naive tumors. Additionally, non-CSCs may undergo cellular plasticity to be reprogrammed to prostate cancer stem cells (PCSCs) during spontaneous tumor progression or upon therapeutic treatments. Consequently, PCSCs may become the predominant population in treatment-resistant tumors, and the \u201croot cause\u201d for drug resistance. microRNA-34a (miR-34a) is a bona fide tumor-suppressive miRNA, and its expression is dysregulated in PCa. Importantly, miR-34a functions as a potent CSC suppressor by targeting many molecules essential for CSC survival and functions, which makes it a promising anti-PCSC therapeutic. Here, we conducted a comprehensive literature survey of miR-34a in the context of PCa and especially PCSCs. We provided an updated overview on the mechanisms of miR-34a regulation followed by discussing its tumor suppressive functions in PCa. Finally, based on current advances in miR-34a preclinical studies in PCa, we offered potential delivery strategies for miR-34a-based therapeutics for treating advanced PCa.<\/jats:p>","DOI":"10.3390\/cancers14184538","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T21:47:27Z","timestamp":1663624047000},"page":"4538","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6906-1256","authenticated-orcid":false,"given":"Wen (Jess)","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"},{"name":"Experimental Therapeutics (ET) Graduate Program, Roswell Park Comprehensive Cancer Center and the University at Buffalo, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2237-1016","authenticated-orcid":false,"given":"Xiaozhuo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Dougherty","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"},{"name":"Genetics & Genomics Graduate Program, Roswell Park Comprehensive Cancer Center and the University at Buffalo, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean G.","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA"},{"name":"Experimental Therapeutics (ET) Graduate Program, Roswell Park Comprehensive Cancer Center and the University at Buffalo, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.semcancer.2021.11.001","article-title":"Understanding and targeting prostate cancer cell heterogeneity and plasticity","volume":"82","author":"Tang","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/cr.2012.13","article-title":"Understanding cancer stem cell heterogeneity and plasticity","volume":"22","author":"Tang","year":"2012","journal-title":"Cell Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41467-018-06067-7","article-title":"Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"23959","DOI":"10.18632\/oncotarget.4260","article-title":"Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.stem.2012.03.009","article-title":"The PSA(-\/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration","volume":"10","author":"Qin","year":"2012","journal-title":"Cell Stem Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1042\/EBC20220003","article-title":"Prostate cancer as a dedifferentiated organ: Androgen receptor, cancer stem cells, and cancer stemness","volume":"66","author":"Liu","year":"2022","journal-title":"Essays Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1158\/1078-0432.CCR-12-2043","article-title":"Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia","volume":"19","author":"Lionetti","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nrd4140","article-title":"MicroRNAs and other non-coding RNAs as targets for anticancer drug development","volume":"12","author":"Ling","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd3179","article-title":"Targeting microRNAs in cancer: Rationale, strategies and challenges","volume":"9","author":"Garzon","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fgene.2012.00120","article-title":"MiR-34\u2014A microRNA replacement therapy is headed to the clinic","volume":"3","author":"Bader","year":"2012","journal-title":"Front. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1038\/s41467-019-13532-4","article-title":"LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer","volume":"10","author":"Li","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"640587","DOI":"10.3389\/fcell.2021.640587","article-title":"MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic","volume":"9","author":"Li","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm.2284","article-title":"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44","volume":"17","author":"Liu","year":"2011","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/nature05939","article-title":"A microRNA component of the p53 tumour suppressor network","volume":"447","author":"He","year":"2007","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.molcel.2007.05.010","article-title":"Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis","volume":"26","author":"Chang","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.molcel.2007.05.017","article-title":"Transcriptional activation of miR-34a contributes to p53-mediated apoptosis","volume":"26","author":"Marciano","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1101\/gad.233585.113","article-title":"A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression","volume":"28","author":"Okada","year":"2014","journal-title":"Genes Dev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1101\/gad.1965810","article-title":"Molecular genetics of prostate cancer: New prospects for old challenges","volume":"24","author":"Shen","year":"2010","journal-title":"Genes Dev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/pros.24353","article-title":"The evolving landscape of prostate cancer somatic mutations","volume":"82","author":"Cotter","year":"2022","journal-title":"Prostate"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","article-title":"Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer","volume":"76","author":"Hamid","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1172\/JCI132031","article-title":"Genomics of lethal prostate cancer at diagnosis and castration resistance","volume":"130","author":"Mateo","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Bott, S.R.J., and Ng, K.L. (2021). Revisiting the Role of p53 in Prostate Cancer. Prostate Cancer, Exon Publications.","DOI":"10.36255\/exonpublications.prostatecancer.2021"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbrc.2008.09.086","article-title":"Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells","volume":"377","author":"Fujita","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4161\/cc.7.16.6533","article-title":"Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer","volume":"7","author":"Lodygin","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Concepcion, C.P., Han, Y.-C., Mu, P., Bonetti, C., Yao, E., D\u2019Andrea, A., Vidigal, J.A., Maughan, W.P., Ogrodowski, P., and Ventura, A. (2012). Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet., 8.","DOI":"10.1371\/journal.pgen.1002797"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ng.2007.30","article-title":"Widespread microRNA repression by Myc contributes to tumorigenesis","volume":"40","author":"Chang","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1182\/blood-2010-10-312231","article-title":"Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1","volume":"117","author":"Craig","year":"2011","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.4161\/cbt.7.8.6284","article-title":"MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer","volume":"7","author":"Rokhlin","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.18632\/oncotarget.3480","article-title":"A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells","volume":"6","author":"Ding","year":"2015","journal-title":"Oncotarget"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/0008-5472.CAN-10-2421","article-title":"Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells","volume":"71","author":"Ostling","year":"2011","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1172\/JCI73531","article-title":"IL-6R\/STAT3\/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis","volume":"124","author":"Rokavec","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3892\/or.2015.4331","article-title":"Methylation-induced silencing of miR-34a enhances chemoresistance by directly upregulating ATG4B-induced autophagy through AMPK\/mTOR pathway in prostate cancer","volume":"35","author":"Liao","year":"2016","journal-title":"Oncol. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e14620","DOI":"10.7554\/eLife.14620","article-title":"A long non-coding RNA targets microRNA miR-34a to regulate colon cancer stem cell asymmetric division","volume":"5","author":"Wang","year":"2016","journal-title":"eLife"},{"key":"ref_37","first-page":"14","article-title":"Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment","volume":"4","author":"Kong","year":"2012","journal-title":"Am. J. Transl. Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Nanni, S., Aiello, A., Re, A., Guffanti, A., Benvenuti, V., Colussi, C., Castro-Vega, L.J., Felsani, A., Londono-Vallejo, A., and Capogrossi, M.C. (2013). Estrogen-dependent dynamic profile of eNOS-DNA associations in prostate cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062522"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/ncb2366","article-title":"MiR-34 miRNAs provide a barrier for somatic cell reprogramming","volume":"13","author":"Choi","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e39479","DOI":"10.7554\/eLife.39479","article-title":"MiR-34a is a microRNA safeguard for Citrobacter-induced inflammatory colon oncogenesis","volume":"7","author":"Wang","year":"2018","journal-title":"eLife"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.celrep.2014.02.023","article-title":"MiR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment","volume":"6","author":"Cheng","year":"2014","journal-title":"Cell Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1158\/0008-5472.CAN-11-3864","article-title":"Distinct microRNA expression profiles in prostate cancer stem\/progenitor cells and tumor-suppressive functions of let-7","volume":"72","author":"Liu","year":"2012","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc1912","article-title":"Comoglio, Invasive growth: A MET-driven genetic programme for cancer and stem cells","volume":"6","author":"Boccaccio","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ncomms1159","article-title":"Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling","volume":"2","author":"Rajasekhar","year":"2011","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1158\/1078-0432.CCR-09-2642","article-title":"Frequent downregulation of miR-34 family in human ovarian cancers","volume":"16","author":"Corney","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"14240","DOI":"10.1073\/pnas.1017536108","article-title":"Wild-type p53 controls cell motility and invasion by dual regulation of MET expression","volume":"108","author":"Hwang","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"29161","DOI":"10.18632\/oncotarget.4971","article-title":"Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy","volume":"6","author":"Gaur","year":"2015","journal-title":"Oncotarget"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Yamamura, S., Saini, S., Majid, S., Hirata, H., Ueno, K., Deng, G., and Dahiya, R. (2012). MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029722"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.biopha.2017.10.163","article-title":"MiR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1","volume":"97","author":"Zhang","year":"2018","journal-title":"Biomed. Pharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1158\/1541-7786.MCR-17-0230","article-title":"miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression","volume":"16","author":"Chakravarthi","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1158\/0008-5472.CAN-13-0615","article-title":"RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer","volume":"73","author":"Civenni","year":"2013","journal-title":"Cancer Res."},{"key":"ref_52","first-page":"8349","article-title":"MiR-34a affects G2 arrest in prostate cancer PC3 cells via Wnt pathway and inhibits cell growth and migration","volume":"24","author":"Dong","year":"2020","journal-title":"Eur. Rev. Med. Pharm. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.18632\/oncotarget.2690","article-title":"MicroRNA-34a regulates WNT\/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cell.2009.04.030","article-title":"WNT\/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis","volume":"138","author":"Nguyen","year":"2009","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1158\/1541-7786.MCR-14-0503","article-title":"LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a","volume":"13","author":"Liang","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1074\/jbc.RA118.006983","article-title":"NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells","volume":"294","author":"Farah","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000494004","article-title":"MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1\/Notch1 Axis","volume":"50","author":"Liu","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Alves-Fernandes, D.K., and Jasiulionis, M.G. (2019). The Role of SIRT1 on DNA Damage Response and Epigenetic Alterations in Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133153"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/1947601913476948","article-title":"Deacetylation by SIRT1 Reprograms Inflammation and Cancer","volume":"4","author":"Liu","year":"2013","journal-title":"Genes Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/pros.21185","article-title":"MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms","volume":"70","author":"Kojima","year":"2010","journal-title":"Prostate"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1158\/0008-5472.CAN-16-2355","article-title":"Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer","volume":"77","author":"Wen","year":"2017","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/pros.22848","article-title":"miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression","volume":"74","author":"Corcoran","year":"2014","journal-title":"Prostate"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer","volume":"17","author":"Levy","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.addr.2013.12.008","article-title":"Liposomal siRNA nanocarriers for cancer therapy","volume":"66","author":"Ozpolat","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"eaam9327","DOI":"10.1126\/scitranslmed.aam9327","article-title":"FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer","volume":"9","author":"Orellana","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"zcab030","DOI":"10.1093\/narcan\/zcab030","article-title":"Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases","volume":"3","author":"Abdelaal","year":"2021","journal-title":"NAR Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10637-016-0407-y","article-title":"Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors","volume":"35","author":"Beg","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"12","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1158\/0008-5472.CAN-10-0655","article-title":"Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34","volume":"70","author":"Wiggins","year":"2010","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1158\/1535-7163.MCT-14-0209","article-title":"Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer","volume":"13","author":"Daige","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"djv303","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 Regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1038\/onc.2014.282","article-title":"A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer","volume":"34","author":"Kasinski","year":"2015","journal-title":"Oncogene"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/mt.2010.136","article-title":"Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy","volume":"18","author":"Chen","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/mt.2011.48","article-title":"Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice","volume":"19","author":"Trang","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1038\/leu.2012.110","article-title":"Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo","volume":"26","author":"Craig","year":"2012","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.biomaterials.2012.12.016","article-title":"Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model","volume":"34","author":"Hu","year":"2013","journal-title":"Biomaterials"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.7150\/thno.20771","article-title":"Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly","volume":"7","author":"Lin","year":"2017","journal-title":"Theranostics"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41467-017-02283-9","article-title":"Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer","volume":"9","author":"Gibori","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1903290","DOI":"10.1002\/advs.201903290","article-title":"Tailored Lipoprotein-Like miRNA Delivery Nanostructure Suppresses Glioma Stemness and Drug Resistance through Receptor-Stimulated Macropinocytosis","volume":"7","author":"Jiang","year":"2020","journal-title":"Adv. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccr.2010.06.016","article-title":"Regulation of tumor angiogenesis by EZH2","volume":"18","author":"Lu","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1158\/1078-0432.CCR-10-0005","article-title":"Targeted gene silencing using RGD-labeled chitosan nanoparticles","volume":"16","author":"Han","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1166\/jbn.2021.3020","article-title":"Ultrasound-Induced Microbubble Cavitation Combined with miR-34a-Loaded Nanoparticles for the Treatment of Castration-Resistant Prostate Cancer","volume":"17","author":"Wang","year":"2021","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1517\/17425247.3.6.713","article-title":"Ultrasound-induced cavitation: Applications in drug and gene delivery","volume":"3","author":"Paliwal","year":"2006","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jconrel.2016.04.034","article-title":"Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy","volume":"232","author":"Yao","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.biomaterials.2018.10.036","article-title":"Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer","volume":"192","author":"Lin","year":"2019","journal-title":"Biomaterials"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41434-021-00275-5","article-title":"rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer progression","volume":"29","author":"Ai","year":"2021","journal-title":"Gene Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber\u2019s congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1359-6446(00)01594-4","article-title":"Folate-mediated targeting: From diagnostics to drug and gene delivery","volume":"6","author":"Leamon","year":"2001","journal-title":"Drug Discov. Today"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","article-title":"Expression of prostate-specific membrane antigen in normal and malignant human tissues","volume":"30","author":"Kinoshita","year":"2006","journal-title":"World J. Surg."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1021\/mp900069d","article-title":"Prostate-Specific Membrane Antigen Targeted Imaging and Therapy of Prostate Cancer Using a PSMA Inhibitor as a Homing Ligand","volume":"6","author":"Kularatne","year":"2009","journal-title":"Mol. Pharm."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1038\/s41598-018-22594-1","article-title":"PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis","volume":"8","author":"Bravaccini","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Sheehan, B., Guo, C., Neeb, A., Paschalis, A., Sandhu, S., and de Bono, J.S. (2021). Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. Eur. Urol. Focus.","DOI":"10.1016\/j.euf.2021.06.006"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","article-title":"Advances in PSMA-targeted therapy for prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1749-6632.2009.04977.x","article-title":"Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues","volume":"1175","author":"Thomas","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA\u2013PET in prostate cancer management","volume":"13","author":"Maurer","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Staniszewska, M., Costa, P.F., Eiber, M., Klose, J., Wosniack, J., Reis, H., Szarvas, T., Hadaschik, B., L\u00fcckerath, K., and Herrmann, K. (2021). Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147431"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/18\/4538\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:34:38Z","timestamp":1760142878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/18\/4538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":96,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["cancers14184538"],"URL":"https:\/\/doi.org\/10.3390\/cancers14184538","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]}}}